TY - JOUR
T1 - Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers
AU - Shigeyasu, Kunitoshi
AU - Toden, Shusuke
AU - Zumwalt, Timothy J.
AU - Okugawa, Yoshinaga
AU - Goel, Ajay
N1 - Funding Information:
The present work was supported by grants R01 CA72851, CA18172, CA184792, and U01 CA187956 from the National Cancer Institute, NIH; funds from the Baylor Research Institute; and a pilot grant from Charles A. Sammons Cancer Center. This work was also supported by grant from Uehara Memorial Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2017 AACR.
PY - 2017/5/15
Y1 - 2017/5/15
N2 - Cancer has emerged as a leading cause of mortality worldwide, claiming more than 8 million lives annually. Gastrointestinal cancers account for about 35% of these mortalities. Recent advances in diagnostic and treatment strategies have reduced mortality among patients with gastrointestinal cancer, yet a significant number of patients still develop late-stage cancer, where treatment options are inadequate. Emerging interests in "liquid biopsies" have encouraged investigators to identify and develop clinically relevant noninvasive genomic and epigenomic signatures that can be exploited as biomarkers capable of detecting premalignant and early-stage cancers. In this context, microRNAs (miRNA), which are small, noncoding RNAs that are frequently dysregulated in cancers, have emerged as promising entities for such diagnostic purposes. Even though the future looks promising, current approaches for detecting miRNAs in blood and other biofluids remain inadequate. This review summarizes existing efforts to exploit circulating miRNAs as cancer biomarkers and evaluates their potential and challenges as liquid biopsy-based biomarkers for gastrointestinal cancers.
AB - Cancer has emerged as a leading cause of mortality worldwide, claiming more than 8 million lives annually. Gastrointestinal cancers account for about 35% of these mortalities. Recent advances in diagnostic and treatment strategies have reduced mortality among patients with gastrointestinal cancer, yet a significant number of patients still develop late-stage cancer, where treatment options are inadequate. Emerging interests in "liquid biopsies" have encouraged investigators to identify and develop clinically relevant noninvasive genomic and epigenomic signatures that can be exploited as biomarkers capable of detecting premalignant and early-stage cancers. In this context, microRNAs (miRNA), which are small, noncoding RNAs that are frequently dysregulated in cancers, have emerged as promising entities for such diagnostic purposes. Even though the future looks promising, current approaches for detecting miRNAs in blood and other biofluids remain inadequate. This review summarizes existing efforts to exploit circulating miRNAs as cancer biomarkers and evaluates their potential and challenges as liquid biopsy-based biomarkers for gastrointestinal cancers.
UR - http://www.scopus.com/inward/record.url?scp=85017685132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017685132&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-1676
DO - 10.1158/1078-0432.CCR-16-1676
M3 - Review article
C2 - 28143873
AN - SCOPUS:85017685132
SN - 1078-0432
VL - 23
SP - 2391
EP - 2399
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -
